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Abstracts / Biol Blood Marrow Transplant 21 (2015) S30eS53 S31relapse, or transplant related mortality (TRM) (p¼0.2, p¼0.1,
p¼0.08, respectively). To investigate why higher CPSS scores
were associated with higher mortality, we performed analysis
restricted to patients with relapse following HCT. Those with
intermediate-2/high riskhadnearly two-fold increase in riskof
death after relapse compared to thosewith low/intermediate-
1 CPSS scores. Corresponding rates for low/intermediate-1 risk
groups,OSat1year, 3years, and5yearswere61%,48%, and44%
respectivelyand for intermediate-2/high riskgroupswere 38%,
32%, and19%respectively.OSofpatientswho receivedpre-HCT
treatment with hypomethylating agents, chemotherapy, or
both was not different compared to those who received no
therapy prior (p¼0.96).
In summary, CPSS scores, lower KPS scores, and bone
marrow as graft source were associated with poorer out-
comes following HCT.
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Introduction: A donor Killer Cell Ig-like Receptor (KIR) B-
Haplotye has been reported to beneﬁcially inﬂuence
outcome of unrelated transplantation for patients with acute
myeloid leukemia (AML) if the recipient HLA-C phenotype
exhibits a C1 ligand. We validated this association in an in-
dependent cohort of German patients.
Materials and Methods: Patients treated with ﬁrst unrelated
transplantation between 2000 and 2009 for a malignant
hematological disease were included (n¼1694, myeloid dis-
ease n¼982e58.0%, lymphatic diseases n¼712 e 42.0%). Graft
sources were bone marrow (n¼132 e 7.8%) or peripheral
blood stem cells (n¼1562e92.2%). All patients and donors
were high resolution typed for the loci HLA-A,B,C,DRB1,DQB1.
Retrospectively, the donors were typed for KIR genes using a
commercial SSP kit (Invitrogen) and classiﬁed for KIR-AA or
KIR-Bx haplotypes based upon the presence of one or more of
the following activating KIR-receptors: 2DL2, 2DL5, 3DS1,
2DS1, 2DS2, 2DS3, 2DS5. The resulting groups were compared
for the endpoints: relapse, transplant-relatedmortality (TRM),
and overall survival (OS) using competing risks analysis and
extended Cox regression modelling for the subsets myeloid
and lymphatic diseases. Heterogeneity of diagnosis within
each subset was adjusted using stratiﬁcation.
Results: For lymphatic diseases no signiﬁcant difference was
found between the corresponding groups regarding relapse,
OS and TRM. For myeloid diseases however, a signiﬁcantly
lower rate of relapse was found if the donor had a KIR Bx
haplotype and the patient had a C1 HLA-C ligand (5 year
relapse rate 36.2% vs 28.2%, p¼0.012). OS and TRM was
slightly favorable for this group, but no signiﬁcant differ-
ences could be found (OS: 42.2% vs. 37.9%, p¼0.146; TRM:
20.8% vs. 22.9% p¼0.433). The effect on relapse was inde-
pendent of the HLA-matching status, and a relative risk rate
of 0.73 (CI 0.57-0.92, p¼0.009) for the incidence of relapse
was found in multivariate competing risks regression after
correction for the number of HLA mismatches.
Conclusion: A substantially reduced relapse ratewas found in
our analysis for patients with myeloid diseases and the pres-
ence of an HLA-C1 ligand if their donor had a KIR-Bx Haplo-
type. Most patients being transplanted fall in this patient
group. Approximately two thirds of all donors have a KIR-Bx
haplotype. For patients with myeloid diseases and an HLA-C1
ligand, donor KIR typing should be performed if more than
one well matched donors are available. Donors with KIR-AA
haplotypes should be avoided for these patients if possible.10
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Figure 1. Cumulative incidence: time to ANC >500.
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Background: The binding of CXCR4 with its ligand (stromal
derived factor-1 [SDF-1]) maintains hematopoietic stem/pro-
genitor cells (HSPCs) in a quiescent state. This effect of CXCR4/
SDF-1 interaction may be undesirable during the early phase
of hematopoietic stem cell transplantation (HSCT). We hy-
pothesized that blocking CXCR4/SDF-1 interaction after HSCT
promotes hematopoiesis by inducing HSPC proliferation. WeFigure 2. Cumulative incidence: time to platelet >20.have found that giving AMD3100 (plerixafor) after HSCT
enhanced recovery of all donor cell lineages in murine
transplant models (Kang, PLOS ONE 2010). We have further
demonstrated that this enhanced donor cell recovery results
from the combined effect of AMD3100 opening the marrow
niche and inducing HSPC cell division. Based on these ﬁnd-
ings, we conducted a phase I/II trial of plerixafor on donor cell
recovery following myeloablative allogeneic HSCT.
Methods: Patients with various hematologic malignancies
receiving myeloablative conditioning were enrolled in the
study. Plerixafor 240 mg/kg subcutaneously every other day
was administered beginning day +2 until day +21 or until
ANC>500. The primary efﬁcacy endpoints of the study were
time to ANC>500 and time to platelets>20k. The cumulative
incidence of neutrophil and platelet engraftment of the study
cohort was compared to that of a historical cohort of 106
patients from the Duke HSCT program who received similar
conditioning and graft-versus host disease prophylaxis. Pre-
engraftment relapse and death were the competing risks.
Gray’s test was used to compare the cohorts.
Results: Twenty-nine patients were evaluated in the study.
Adverse events attributable to plerixafor were mild in nature
and expected (GI upset, nausea, diarrhea, fatigue, and in-
jection site reactions). They were difﬁcult to distinguish from
effects of the myeloablative conditioning regimen. There
were no dose limiting toxicities of premature ventricular
arrhythmias, primary or secondary graft failure, or mortality
associated with plerixafor administration. Engraftment ki-
netics as demonstrated by cumulative incidence showed a
trend toward faster neutrophil engraftment (p¼0.07) and
quicker platelet recovery >20K (p¼0.04) Figures 1 and 2.
Median time to ANC>500 with 95% CI for plerixafor treat-
ment group and historical control group was 17 days (16, 18)
and 17 days (16, 19), respectively. Median time to platelet
count >20 was 18 days (15, 22) in the treatment cohort and
19 days (19, 21) historically. Transplant related mortality
calculated at Day +100 with 95% CI was 0.069 (0.00, 0.157).
Conclusion: In this study, there appeared to be limited tox-
icities with plerixafor following myeloablative HSCT. Plerix-
afor enhances platelet recovery, and may enhance neutrophil
recovery as well. This study provides proof of principle that
blocking CXCR4 after HSCT enhances hematopoietic recovery.
Larger, conﬁrmatory studies are justiﬁed.11
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Background: Currently, the thalassemia free survival rate
after hematopoietic stem cell transplant (HSCT) is about 80-
90%with either matched sibling or unrelated donor. However,
the probability to ﬁnd a suitable door is only 25-50%. Since
most of these patients (pts) could not ﬁnd the potential donor,
we would like to investigate the haplo-SCT in thalassemia.
Patients and Methods: Between Jan 2013 and October 2014,
15 thalassemia patients (pts) underwent haplo-SCT. Eight
subjects were male and 7 were female. The median age was
16 yrs (range; 2-22). Eleven of 15 received stem cells from
mother and 4 from father. Twelve of 15were high risk class 3.
